Biogen to discontinue development of older Alzheimer’s drug Aduhelm
(Reuters) – Biogen Inc said on Wednesday it would terminate a post-approval study of its first Alzheimer’s drug, Aduhelm, and discontinue all commercialization for the controversial treatment. The strategic shift will help…
Down syndrome families’ fight for access to Alzheimer’s trials, treatments
By Julie Steenhuysen CHICAGO (Reuters) – When Lianor da Cunha Hillerstrom of Lexington, Massachusetts, learned her now 9-year-old son Oskar had Down syndrome, she was concerned but not panicked. As a child,…
Newark Police Seek Assistance in Locating Missing 70-Year-Old Man with Alzheimer’s
NEWARK, NJ – Newark Public Safety Director Fritz G. Fragé has issued an urgent appeal to the public for assistance in locating 70-year-old Errol Bryan, who was reported missing on Saturday, August…
Major US health systems expect to offer Alzheimer’s drug Leqembi in a few months
By Julie Steenhuysen and Deena Beasley CHICAGO (Reuters) – Five major U.S. health systems said they would offer Eisai and Biogen’s promising new Alzheimer’s drug Leqembi after working out payment and administrative…
Factbox-Companies in Alzheimer’s race after US nod for Eisai/Biogen drug
(Reuters) – Eisai Co Ltd and Biogen Inc’s Leqembi emerged as the first Alzheimer’s treatment to win the U.S. Food and Drug Administration’s standard approval on Thursday, a milestone in drug development…
Explainer-Who is eligible for the new FDA-approved Alzheimer’s drug?
By Deena Beasley The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen’s Leqembi for patients with Alzheimer’s disease. The FDA decision is expected to trigger broader…
Medicare offers details on reimbursement for new Alzheimer’s drugs
By Julie Steenhuysen CHICAGO (Reuters) -The U.S. Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai Co Ltd and Biogen Inc’s…
After weight loss, Alzheimer’s may be next frontier for drugs like Ozempic
By Natalie Grover LONDON (Reuters) – Diabetes drugs that also promote weight loss such as Novo Nordisk’s Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of…
Exclusive-Lilly expects US Medicare to reverse course, fully cover Alzheimer’s drugs
By Deena Beasley and Julie Steenhuysen (Reuters) – Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer’s drugs as more evidence…
JAMES CARTER AND JAMES PINKERTON: There’s A Major Obstacle To Finding The Cure For Alzheimer’s
JAMES CARTER AND JAMES PINKERTON: There’s A Major Obstacle To Finding The Cure For Alzheimer’s James Carter And James Pinkerton on March 4, 2023 Three years ago, one of us (Carter) co-authored…
Eisai, Biogen’s Alzheimer’s drug price should not dent demand – analysts
(Reuters) – The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc’s newly approved Alzheimer’s disease drug is slightly above expectations, but should not dent demand for the promising therapy, Wall…
Eisai files for full FDA approval for Alzheimer’s drug Leqembi
(Reuters) – Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer’s drug Leqembi, which…
Factbox-Who can get the newly approved Eisai and Biogen Alzheimer’s drug?
(Reuters) – The U.S. Food and Drug Administration on Friday approved Eisai Co Ltd and Biogen Inc’s Alzheimer’s drug lecanemab for the treatment of early forms of the fatal, brain-wasting disease. Like…
Roche shutters most trials of Alzheimer’s drug after failed trials
By Julie Steenhuysen CHICAGO (Reuters) – Swiss drugmaker Roche is closing down most clinical trials of its experimental Alzheimer’s drug gantenerumab after it failed to slow advance of the mind-robbing disease in…
Eisai, Biogen Alzheimer’s drug could be available to some next year
By Deena Beasley and Julie Steenhuysen SAN FRANCISCO (Reuters) – Japan’s Eisai Co plans to seek full approval of its experimental Alzheimer’s drug lecanemab in the United States, Europe and Japan armed…
Rare success for Alzheimer’s research unlocks hope for future therapies
By Julie Steenhuysen CHICAGO (Reuters) -The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the…
73-year-old man with Alzheimers reported missing in Newark
By Newark PD, Newark Public Safety Director Fritz G. Fragé seeks the public’s help in locating Rafael Rivera, 73, who was reported missing today, Friday, November 4, 2022. Mr. Rivera, who suffers…
Analysis-Eisai’s trial success raises hope for Alzheimer’s prevention
By Julie Steenhuysen CHICAGO (Reuters) – Clear evidence this week that Eisai and Biogen’s drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer’s researchers toward a tantalizing…
83-Year-Old Alzheimer’s Patient Reported Missing in Newark
NEWARK, NJ – Police in Newark have issued a silver alert for a missing 83-year-old man named Felix Perez, who went missing earlier in the day. “Mr. Perez, who suffers from Alzheimer’s,…
Biogen CEO to leave as Alzheimer’s drug struggles
(Reuters) – Biogen said on Tuesday its Chief Executive Michel Vounatsos will step down, with the drugmaker adding it would scale down its sales infrastructure for the controversial Alzheimer’s drug Aduhelm. Below…
Alzheimer’s patient groups pressure U.S. to pay for Biogen drug
By Deena Beasley – Patient groups are mounting a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s treatments, spending millions of dollars on television…
REPORT: Biogen, Eisai Began Application For Alzheimer’s Drug
Biogen, and its Japanese partner Eisai, announced Monday that it plans to begin the process for U.S. approval for its experimental drug for Alzheimer’s. Biogen and Eisai announced “rolling submission” to the…
Breaking News
